Toronto, Canada, 11 June, 2019:
MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments. The latest LAB150 project builds on years of research led by Dr. José Nobrega at CAMH, a MaRS Innovation member organisation. Dr. Nobrega has been focused on targeting a specific channel in the brain that plays a key role in mediating emotional and stress responses.
LAB150 accelerates academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms and expertise. For further information on the new LAB150 projects, click here for LAB150's newsroom.